By the numbers: 70% of the people we surveyed say they’ve used the internet to research symptoms or learn more about health conditions. And 51% use apps or other tech tools to track their sleep, fitness or diet.
But as people’s needs shift from personal information-gathering into the formal health care system, their tech usage begins to fall.
Only 44% have accessed their medical records online, and fewer than 25% have used the internet to manage chronic conditions, mental health, or their health care spending.
Yes, but: Across the board, young people are more likely to go online for some part of their health care needs.
Nearly half of 18-44 year-olds, for example, have used the internet to research a provider — compared with just 32% of patients older than 45.
The big picture: In Silicon Valley, where I have lived and worked for over 25 years, “disruption” is a buzzword and a goal unto itself. And in health tech, promises of “disruption” run the gamut from coverage to payment to actual care.
Apple, Eli Lilly and a startup called Evidation Health recently announced plans for an iPhone and Apple Watch feature they say could help detect Alzheimer’s.
Startups like San Francisco-based Forward offer concierge primary care that uses a slew of high-tech tools, in an office modeled on the experience of using an app.
And of course there’s the most famous example of a failed promise of disruptive health tech: Theranos.
The bottom line: It’s time to pay close, serious attention to what is real and what is hype in health tech.
This conversation, which has been the province of investors, tech companies and the business press, warrants more serious and objective questions about the effects on people’s health, privacy, and their health spending.
Elizabeth Holmes arrives at federal court in San Jose, Calif. on June 28. (Photo: Justin Sullivan/Getty Images)
Theranos Inc. founder Elizabeth Holmes aims to "put investigative journalism on trial" to defend herself against "massive" criminal fraud charges, Bloomberg's Joel Rosenblatt reports.
What's happening, per Bloomberg: "Holmes contends Wall Street Journal reporter John Carreyrou had an undue influence on federal regulators who concluded her blood-testing startup’s technology was a threat to patient health."
"As she prepares for a trial set for July 28, 2020, Holmes is trying to retrace the steps the reporter took to publish his 2015 scoop."
"Through pretrial information sharing with prosecutors, Holmes has unearthed Carreyrou’s early contacts with New York state regulators and various federal agencies, as well as his interactions and emails with a doctor in Arizona."
The bottom line: Holmes and former Theranos president Ramesh “Sunny” Balwani were indicted last year on 11 counts of conspiracy and wire fraud and accused of criminally defrauding investors, patients and doctors. This is the "largest alleged fraud ever perpetrated in Silicon Valley," per Axios' Dan Primack.
